Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Gilead Sciences, Inc. (GILD) – Gilead Sciences, Inc. Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Gilead Sciences (GILD) trades at $131.33, down 2.04% on the day, with strong fundamentals including 30.99% net income margin and consistent earnings beats. The stock shows a bullish technical signal despite recent weakness, with analyst consensus strongly favoring buy ratings. Recent Q1 2026 earnings of $2.03 per share exceeded expectations, though the company lowered full-year EPS guidance due to acquisition-related charges.
GILD presents a compelling investment case with robust profitability and analyst support, but faces near-term headwinds from acquisition integration costs and guidance revision. The 23% upside to consensus price target of $162.10 offers potential reward, balanced against execution risks in a competitive biopharmaceutical landscape.
Read full analysis

Key Stats

  • Market Cap
    $163.06B
  • Sector
    Health
  • 3M Drawdown
    -17.72%
  • Enterprise Value
    $177.59B
  • Dividend Yield
    2.5%
  • Typical Hold Time
    92 days
$133.7
52W Low: $96.91
09 May 2025
52W High: $155.8
11 Feb 2026

Gilead Sciences, Inc. (GILD) is currently valued at a market capitalization of $163.06B, with an enterprise value of $177.59B. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $96.91 and a high of $155.8, highlighting its annual price range. Over the past three months, Gilead Sciences, Inc. has recorded a drawdown of -17.72%, reflecting recent price volatility. Gilead Sciences, Inc. offers a dividend yield of 2.5%, with the most recent dividend of $0.82 paid on 13 Mar 26. On average, investors hold Gilead Sciences, Inc. for approximately 92 days, indicating typical investor behavior on the platform.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.


Technical Indicators
|
|
|
Overall Summary
Bearish (6)Neutral (6)Bullish (15)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $163.06B
  • Sector
    Health
  • 3M Drawdown
    -17.72%
  • Enterprise Value
    $177.59B
  • Dividend Yield
    2.5%
  • Typical Hold Time
    92 days
$133.7
52W Low: $96.91
09 May 2025
52W High: $155.8
11 Feb 2026

Gilead Sciences, Inc. (GILD) is currently valued at a market capitalization of $163.06B, with an enterprise value of $177.59B. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $96.91 and a high of $155.8, highlighting its annual price range. Over the past three months, Gilead Sciences, Inc. has recorded a drawdown of -17.72%, reflecting recent price volatility. Gilead Sciences, Inc. offers a dividend yield of 2.5%, with the most recent dividend of $0.82 paid on 13 Mar 26. On average, investors hold Gilead Sciences, Inc. for approximately 92 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!